LungVITamin D and OmegA-3 Trial (lungVITAL) (NCT01728571)
LungVITamin D and OmegA-3 Trial
🩺 Plain-English Summary (8th-Grade Level)
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine whether vitamin D or fish oil reduces respiratory morbidity, including COPD and asthma exacerbations, the risk of pneumonia, and airflow obstruction/decline of pulmonary function; and whether either of these interventions improves asthma control.
Who can join: Review the eligibility criteria below.
Location: Brigham and Women's Hospital — Boston, Massachusetts
Age range: 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Brigham and Women's Hospital — Boston, Massachusetts
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in COPD
- Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound — Calgary,
- Impairments That Affect Correct Inhaler Use in COPD — Birmingham, Alabama
- The Development of an Integrated Physical Activity and Mental Health Intervention for Veterans With COPD, Emotion Distress, and Low Physical Activity — Boston, Massachusetts
- A Study to Evaluate Solrikitug in Participants With COPD (ZION) — Birmingham, Alabama
- RELVAR Effects on Parasternal Muscle Activity, Diaphragm, and Ventilation in Severe COPD — Calgary, Alberta
- Evaluation of the Safety and Efficacy of TLD in Patients with COPD — Birmingham, Alabama
Explore by condition: All COPD clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.